1. < Home

cardiovascular diseases

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

Weitz JI, Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin DA. Biomarkers to predict risk of venous thromboembolism[...]

By sjmartinez • November 3, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas[...]

By sjmartinez • September 22, 2022
Dietary Meat, Trimethylamine N-Oxide-Related Metabolites, and Incident Cardiovascular Disease Among Older Adults: The Cardiovascular Health Study

Wang M, Wang Z, Lee Y, Lai HTM, de Oliveira Otto MC, Lemaitre RN, Fretts A, Sotoodehnia N, Budoff M, DiDonato JA, McKnight B, Tang[...]

By sjmartinez • August 1, 2022
Racial and Ethnic Differences in All-Cause and Cardiovascular Disease Mortality: The MESA Study

Post WS, Watson KE, Hansen S, Folsom AR, Szklo M, Shea S, Barr RG, Burke G, Bertoni AG, Allen N, Pankow JS, Lima JAC, Rotter[...]

By sjmartinez • July 19, 2022
Distribution of Coronary Artery Calcium by Age, Sex, and Race Among Patients 30-45 Years Old

Javaid A, Dardari ZA, Mitchell JD, Whelton SP, Dzaye O, Lima JAC, Lloyd-Jones DM, Budoff M, Nasir K, Berman DS, Rumberger J, Miedema MD, Villines[...]

By rosaguerrero • May 14, 2022
Week 4: Our Commitment to Our Community

I continue to be energized as I learn more about the Department and UCLA that will inform our strategic goals. I want to share some[...]

By sjmartinez • January 31, 2022